20 June 2022
Iofina plc
("Iofina", the "Company" or the "Group")
(LSE AIM: IOF)
Appointment of Chrystal Capital Partners LLP as Strategic Financial Advisor
Iofina plc, manufacturers of specialty chemical products and specialists in the exploration and production of iodine, today announces the appointment of Chrystal Capital Partners LLP ("Chrystal Capital") as a financial advisory partner. Chrystal Capital will be providing strategic advice on the Company's approach to the equity markets and business growth, including helping to engage with new investment funds, Single Family Offices (SFOs), and Ultra High Net Worth Individuals (UHNWIs).
Iofina is one of the lowest cost raw iodine and iodine derivative companies in the world. With spot iodine prices recently reaching $70/kg and demand high for iodine derivatives, market conditions are in Iofina's favour. Debt has been significantly reduced, and with five iodine productions plants in operation and vertical integration into iodine derivatives through Iofina Chemical, along with plans for additional iodine plants, the Company is in its strongest ever position.
Against this backdrop, in addition to organic growth within our core businesses, the Company will further explore business partnerships and combinations in the market and explore wider opportunities to drive shareholder value with the support of Chrystal Capital.
Commenting, President and CEO Dr. Tom Becker, stated: "Over the past few years we have worked hard to position Iofina as one of the lowest cost iodine producers in the world in a market that continues to show solid growth. The appointment of Chrystal Capital Partners solidifies our intent to consider and evaluate opportunities to grow the business beyond our organic growth plans. We look forward to working closely with Chrystal Capital to assess how we can further unlock and drive shareholder value going forward".
Kingsley Wilson, Partner at Chrystal Capital Partners, stated: "Having been involved with Iofina as a private company, and subsequently bringing it to the London market in 2008, I'm personally delighted to be working with the Iofina management team again to assist in the next stage of growth to build value. The iodine and iodine derivatives market globally is in robust health and there are multiple opportunities for Iofina, with a strong market reputation and solid financial strength, to take advantage of to scale the existing business. We look forward to working with the Company to assess and execute its strategic plan".
Enquiries:
Dr. Tom Becker
CEO & President
Iofina plc
Tel: +1 859 356 8000
Christopher Raggett/Tim Harper (Corporate Finance)
Tim Redfern/Barney Hayward (ECM)
finnCap Ltd
Tel: +44 (0)20 7220 0500
Kingsley Wilson
Chrystal Capital Partners LLP
Tel: +44 (0)20 7850 4760
Media Contact:
Charles Goodwin/Laurie Gelhorn
Yellow Jersey PR Limited
Tel: +44 (0)7747 788 221
About Iofina:
Iofina plc (AIM: IOF) is a vertically integrated Company that specialises in the production of Iodine and the manufacturing of specialty chemical products. Iofina is the second largest producer of iodine in North America and operates the manufacturing entities Iofina Resources and Iofina Chemical.
LEI: 213800QDMFYVRJYYTQ84
ISIN: GB00B2QL5C79
Iofina Resources
Iofina Resources develops, builds, owns and operates iodine extraction plants using Iofina's WET® IOsorb® technology. Iofina currently operates five producing IOsorb® plants in Oklahoma and is consistently using technology and innovation to improve and expand its operations.
Iofina Chemical
Iofina Chemical has manufactured high quality halogen specialty chemicals derived from raw iodine, as well as non-iodine based products for over 38 years.
About Chrystal Capital Partners LLP:
Chrystal Capital Partners LLP ("Chrystal"), is an entrepreneurial corporate finance and investment house with an established global network of Single Family Offices, Ultra High Net Worth Individuals and private equity co-investment partners. Chrystal's core sector focus are Digital Economy, Health & Wellness and Sustainable & Impact Investments.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.